Patients receiving higher doses of DNAM⁺CD56^dim NK cells per kg within stem cell product demonstrate a reduced incidence of disease relapse. The patient cohort was divided into patients who relapsed or remained in remission within 2 years posttransplant. Populations of CD56^dim NK cells from the stem cell product expressing NKG2D and NKp46 did not associate with relapse, but DNAM- and KIR-expressing cells did (n = 71 for all phenotypic markers).